These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 18708295

  • 1. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.
    Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, Severens JL, Adang EM, van der Kaa CH, Fütterer JJ, Barentsz J.
    Lancet Oncol; 2008 Sep; 9(9):850-6. PubMed ID: 18708295
    [Abstract] [Full Text] [Related]

  • 2. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging.
    Heesakkers RA, Jager GJ, Hövels AM, de Hoop B, van den Bosch HC, Raat F, Witjes JA, Mulders PF, van der Kaa CH, Barentsz JO.
    Radiology; 2009 May; 251(2):408-14. PubMed ID: 19401573
    [Abstract] [Full Text] [Related]

  • 3. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer.
    Triantafyllou M, Studer UE, Birkhäuser FD, Fleischmann A, Bains LJ, Petralia G, Christe A, Froehlich JM, Thoeny HC.
    Eur J Cancer; 2013 Feb; 49(3):616-24. PubMed ID: 23084842
    [Abstract] [Full Text] [Related]

  • 4. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging.
    Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, Hulsbergen van de Kaa CA, Kaufmann D, Barentsz JO.
    Radiology; 2004 Nov; 233(2):449-56. PubMed ID: 15375228
    [Abstract] [Full Text] [Related]

  • 5. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.
    Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.
    Prostate; 2015 Dec; 75(16):1934-40. PubMed ID: 26356236
    [Abstract] [Full Text] [Related]

  • 6. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
    Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F.
    Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610
    [Abstract] [Full Text] [Related]

  • 7. The importance of the extent of pelvic-lymph-node dissection in the diagnosis of lymph-node metastases in prostate cancer.
    Briganti A, Rigatti P, Montorsi F.
    Lancet Oncol; 2008 Oct; 9(10):915-7; author reply 917-8. PubMed ID: 19071244
    [No Abstract] [Full Text] [Related]

  • 8. Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10.
    Tatsumi Y, Tanigawa N, Nishimura H, Nomura E, Mabuchi H, Matsuki M, Narabayashi I.
    Gastric Cancer; 2006 Oct; 9(2):120-8. PubMed ID: 16767368
    [Abstract] [Full Text] [Related]

  • 9. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.
    Fortuin AS, Deserno WM, Meijer HJ, Jager GJ, Takahashi S, Debats OA, Reske SN, Schick C, Krause BJ, van Oort I, Witjes AJ, Hoogeveen YL, van Lin EN, Barentsz JO.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):712-8. PubMed ID: 22417806
    [Abstract] [Full Text] [Related]

  • 10. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.
    Van den Bergh L, Lerut E, Haustermans K, Deroose CM, Oyen R, Isebaert S, Budiharto T, Ameye F, Mottaghy FM, Bogaerts K, Van Poppel H, Joniau S.
    Urol Oncol; 2015 Mar 01; 33(3):109.e23-31. PubMed ID: 25655681
    [Abstract] [Full Text] [Related]

  • 11. Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT.
    Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Barentsz JO.
    Eur Radiol; 2004 Sep 01; 14(9):1707-12. PubMed ID: 15249979
    [Abstract] [Full Text] [Related]

  • 12. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients.
    Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, Fleischmann A, Vermathen P, Studer UE.
    Eur Urol; 2009 Apr 01; 55(4):761-9. PubMed ID: 19144456
    [Abstract] [Full Text] [Related]

  • 13. Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging.
    Thoeny HC, Froehlich JM, Triantafyllou M, Huesler J, Bains LJ, Vermathen P, Fleischmann A, Studer UE.
    Radiology; 2014 Oct 01; 273(1):125-35. PubMed ID: 24893049
    [Abstract] [Full Text] [Related]

  • 14. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer.
    Birkhäuser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, Vermathen P, Fleischmann A, Thoeny HC.
    Eur Urol; 2013 Dec 01; 64(6):953-60. PubMed ID: 23916692
    [Abstract] [Full Text] [Related]

  • 15. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT.
    Borley N, Fabrin K, Sriprasad S, Mondaini N, Thompson P, Muir G, Poulsen J.
    Scand J Urol Nephrol; 2003 Dec 01; 37(5):382-6. PubMed ID: 14594685
    [Abstract] [Full Text] [Related]

  • 16. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging.
    Dinniwell R, Chan P, Czarnota G, Haider MA, Jhaveri K, Jewett M, Fyles A, Jaffray D, Milosevic M.
    Int J Radiat Oncol Biol Phys; 2009 Jul 01; 74(3):844-51. PubMed ID: 19095369
    [Abstract] [Full Text] [Related]

  • 17. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide.
    Nishimura H, Tanigawa N, Hiramatsu M, Tatsumi Y, Matsuki M, Narabayashi I.
    J Am Coll Surg; 2006 Apr 01; 202(4):604-11. PubMed ID: 16571430
    [Abstract] [Full Text] [Related]

  • 18. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?
    Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, Weissleder R.
    AJR Am J Roentgenol; 2006 Jan 01; 186(1):144-8. PubMed ID: 16357394
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Harada T, Tanigawa N, Matsuki M, Nohara T, Narabayashi I.
    Eur J Radiol; 2007 Sep 01; 63(3):401-7. PubMed ID: 17398053
    [Abstract] [Full Text] [Related]

  • 20. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
    Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, Oyen R, Ameye F, Bogaerts K, Haustermans K, Van Poppel H.
    Eur Urol; 2011 Jul 01; 60(1):125-30. PubMed ID: 21292388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.